Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy
Clinical trial NCT06317298 · UNKNOWN
Trial details
- NCT number
- NCT06317298
- Sponsor
- Peking University First Hospital
- Status
- UNKNOWN
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-21
- Primary completion
- 2025-08-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.